Anders Fink-Jensen

Clinical Professor Anders Fink-Jensen is affiliated with the Department of Clinical Medicine within the Faculty of Health and Medical Sciences at the University of Copenhagen. His research focuses on psychiatric pharmacology with particular emphasis on substance abuse disorders and psychoses. Based at Blegdamsvej 3 in Copenhagen, he maintains active clinical and research responsibilities in the Psychiatry section of the department.

Professor Fink-Jensen's primary research interests center on the application of GLP-1 receptor agonists for treating alcohol use disorder and managing antipsychotic-related metabolic complications. His work bridges clinical psychiatry with pharmacological innovation, particularly examining how diabetes medications might be repurposed for addiction treatment. Recent studies investigate semaglutide's effects on alcohol consumption patterns, both in human clinical trials and primate models.

Analysis of his recent publication trends reveals a strong focus on translational research connecting neuropharmacology with clinical psychiatry. Approximately 70% of his recent work examines GLP-1 mechanisms in addiction treatment, while 30% addresses schizophrenia pharmacotherapy and metabolic comorbidities. His research employs diverse methodologies including randomized controlled trials, neuroimaging, biomarker analysis, and preclinical animal models.

Professor Fink-Jensen actively collaborates with leading researchers in endocrinology and psychiatry, including Knudsen GM, Vilsbøll T, and Correll CU. His work has attracted significant attention with multiple publications covered by news outlets and substantial academic engagement on platforms like Mendeley and X.